文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

红铁酮与铁调素在异基因造血干细胞移植中介导红细胞生成与铁代谢

Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
PubMed 文献 · Am J Hematol · 2021-08-24

该研究纳入70例接受异基因造血干细胞移植的患者,随机分为促红细胞生成素治疗组与无促红细胞生成素组,纵向检测铁调素、红铁酮、CRP、可溶性转铁蛋白受体、血清铁、转铁蛋白饱和度及铁蛋白。结果显示红铁酮与可溶性转铁蛋白受体及网织红细胞相关,与铁调素呈负相关;铁调素在预处理后达峰、植入期下降,且主要受铁状态与红细胞生成影响,炎症作用不明显。

要点

  • 红铁酮与红系活性指标(sTfR、网织红细胞)正相关,与铁调素负相关。
  • 铁调素在预处理后升高、植入期下降,主要受铁蛋白与红系活性影响。
  • 促红细胞生成素治疗未显著改变红铁酮与铁调素水平。

核心结论

  • 异基因造血干细胞移植后红铁酮与铁调素发生显著变化,红铁酮与红系活性相关并负向调节铁调素。

研究设计与样本

  • 70例异基因造血干细胞移植患者随机分为促红细胞生成素治疗组与无促红细胞生成素组,纵向检测铁调素、红铁酮、CRP、可溶性转铁蛋白受体、血清铁、转铁蛋白饱和度及铁蛋白。

主要发现

  • 红铁酮与可溶性转铁蛋白受体及网织红细胞相关,与铁调素呈负相关。
  • 红铁酮在预处理期间下降,随植入恢复;铁调素在预处理后达峰,植入期下降。
  • 有无促红细胞生成素治疗时红铁酮与铁调素无显著差异。
  • 多变量分析显示红铁酮的主要决定因素是红细胞生成(可溶性转铁蛋白受体、网织红细胞或血清促红细胞生成素)。
  • 移植前铁调素与既往红细胞输注及铁蛋白相关;移植后铁调素主要决定因素为铁状态(各时间点铁蛋白及第56天转铁蛋白饱和度)与红细胞生成,炎症影响不明确。

临床怎么用

  • 监测红铁酮与铁调素有助于理解移植后红细胞生成与铁代谢的动态变化。
  • 移植前铁蛋白高的患者移植后铁调素持续升高,提示铁负荷管理需关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic cell transplantation (HCT) brings important alterations in erythropoiesis and iron metabolism. Hepcidin, which regulates iron metabolism, increases in iron overload or inflammation and decreases with iron deficiency or activated erythropoiesis. Erythroferrone (ERFE) is the erythroid regulator of hepcidin. We investigated erythropoiesis and iron metabolism after allogeneic HCT in 70 patients randomized between erythropoietin (EPO) treatment or no EPO, by serially measuring hepcidin, ERFE, CRP (inflammation), soluble transferrin receptor (sTfR, erythropoiesis), serum iron and transferrin saturation (Tsat; iron for erythropoiesis) and ferritin (iron stores). We identified biological and clinical factors associated with serum hepcidin and ERFE levels. Serum ERFE correlated overall with sTfR and reticulocytes and inversely with hepcidin. Erythroferrone paralleled sTfR levels, dropping during conditioning and recovering with engraftment. Inversely, hepcidin peaked after conditioning and decreased during engraftment. Erythroferrone and hepcidin were not significantly different with or without EPO. Multivariate analyses showed that the major determinant of ERFE was erythropoiesis (sTfR, reticulocytes or serum Epo). Pretransplant hepcidin was associated with previous RBC transfusions and ferritin. After transplantation, the major determinants of hepcidin were iron status (ferritin at all time points and Tsat at day 56) and erythropoiesis (sTfR or reticulocytes or ERFE), while the impact of inflammation was less clear and clinical parameters had no detectable influence. Hepcidin remained significantly higher in patients with high compared to low pretransplant ferritin. After allogeneic HCT with or without EPO therapy, significant alterations of hepcidin occur between pretransplant and day 180, in correlation with iron status and inversely with erythroid ERFE.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pirotte M, Fillet M, Seidel L, et al. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. Am J Hematol. 2021. PMID: 34310730. doi:10.1002/ajh.26300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。